Results 41 to 50 of about 15,914 (251)
Frontiers in Oncology, 2018 Radiation-induced chromosomal aberrations represent an early marker of late effects, including cell killing and transformation. The measurement of cytogenetic damage in tissues, generally in blood lymphocytes, from patients treated with radiotherapy has ...
Marco Durante, Silvia C. Formenti
doaj +1 more source
Monoclonal antibodies for copper-64 PET dosimetry and radioimmunotherapy [PDF]
, 2011 BACKGROUND: We previously described a two-antibody model of (64)Cu radioimmunotherapy to evaluate low-dose, solid-tumor response. This model was designed to test the hypothesis that cellular internalization is critical in causing tumor cell death by ...
Anderson CJ +14 more
core +3 more sources
Re-188 Enhances the Inhibitory Effect of Bevacizumab in Non-Small-Cell Lung Cancer
Molecules, 2016 The malignant behaviors of solid tumors such as growth, infiltration and metastasis are mainly nourished by tumor neovascularization. Thus, anti-angiogenic therapy is key to controlling tumor progression.
Jie Xiao +8 more
doaj +1 more source
A rapid microwave-assisted procedure for easy access to Nx polydentate ligands for potential application in α-RIT [PDF]
, 2010 International audienceHeterocycles bearing a hydrazine moiety react with bisaldehydes or bisketones to afford new Nx polydentate ligands suitable for α-radioimmunotherapy.
Bodio, E. +6 more
core +4 more sources
CD147/Basigin: From Integrative Molecular Hub to Translational Therapeutic Target
Advanced Science, EarlyView.This review conceptualizes CD147 as a fundamental “Energy‐Structure Coupler,” physically bridging metabolic flux (via MCTs) with morphogenetic plasticity (via integrins/MMPs) to drive cancer, infection, and autoimmunity. Addressing the “specificity paradox” that limits current translation, the authors chart a strategic roadmap—spanning logic‐gated ...
Xiang‐Min Yang +2 more
wiley +1 more source
CD38‐Targeted Theranostics of Lymphoma with 89Zr/177Lu‐Labeled Daratumumab
Advanced Science, 2021 Lymphoma is a heterogeneous disease with varying clinical manifestations and outcomes. Many subtypes of lymphoma, such as Burkitt′s lymphoma and diffuse large B cell lymphoma, are highly aggressive with dismal prognosis even after conventional ...
Lei Kang +13 more
doaj +1 more source
Nanotechnology and cancer [PDF]
, 2008 The biological picture of cancer is rapidly advancing from models built from phenomenological descriptions to network models derived from systems biology, which can capture the evolving pathophysiology of the disease at the molecular level.
Davis, Mark E., Heath, James R.
core +2 more sources
Molecular theranostics: principles, challenges and controversies
Journal of Medical Radiation Sciences, Volume 72, Issue 1, Page 156-164, March 2025.Molecular theranostics offers a powerful tool to drive precision medicine in nuclear oncology. While theranostics is not a new principle in nuclear medicine, recent advances in instrumentation and radiopharmacy have driven a reinvigoration and a broader suite of applications.
Geoffrey Currie
wiley +1 more source
Recent Advances in Hepatocellular Carcinoma Treatment with Radionuclides
Pharmaceuticals, 2022 As the third leading cause of cancer death worldwide, hepatocellular carcinoma (HCC) is characterized by late detection, difficult diagnosis and treatment, rapid progression, and poor prognosis.
Ruiqi Liu +4 more
doaj +1 more source
Early Diagnosis of Alzheimer's disease by NIRF Spectroscopy and Nuclear Medicine [PDF]
, 2011 There is an urgent need for the early detection of diseases such as Alzheimer’s (AD) and Cancers in order to enable their successful treatment. Cancer is the second major cause of death after Heart Disease, and AD is the third major cause of death
I. C. Baianu
core +1 more source